Abstract:BackgroundInterstitial lung disease (ILD) is a common and frequently fatal extra-muscular complication in patients with idiopathic inflammatory myopathy (IIM), and is refractory to the conventional immunosuppressive medications. Nintedanib has previously been proven to be effective and tolerable in idiopathic pulmonary fibrosis, systemic-sclerosis-related ILD, etc. However, the efficacy and safety of nintedanib in idiopathic-inflammatory-myopathy-related ILD (IIM-ILD) remain unknown. The purpose of this study was to initially explore the efficacy and tolerability of nintedanib in IIM-ILD patients.MethodsA real-world analysis was conducted to explore the efficacy and tolerability of nintedanib in IIM-ILD patients who regularly received outpatient visit or hospitalization from January 2018 to October 2019 in one medical center. The primary end point was occurrence of rapid progression of interstitial lung disease (RP-ILD) in the follow-up. And time to death from any cause, complication of pulmonary infection and difference in immunosuppressive regimen were taken as secondary end points in this study. Adverse events were descriptively recorded.Results22 patients receiving nintedanib therapy and 82 patients under conventional medications were included. After propensity score matching, the primary comparison revealed that better survival (P = 0.036) and prominently less RP-ILD (P = 0.031) in patients with nintedanib therapy. Logistic regression analysis identified that disease activity (P = 0.032), anti-PM-Scl75 antibody (P = 0.027) and nintedanib therapy (P = 0.023, OR value = 0.063) were significantly correlated with RP-ILD. Cox proportional hazards regression analysis demonstrated that disease activity (P = 0.007), anti-MDA5 antibody (P = 0.004) and nintedanib therapy (P = 0.027, HR value = 0.190) were significantly associated with survival of IIM-ILD patients. Similar results can also be seen in analyses before propensity score matching. In the 22 patients with nintedanib therapy, diarrhea was the most common adverse event (54.5%) and hepatic insufficiency contributed to most dosage reduction (50%) or therapy discontinuation (50%).ConclusionNintedanib therapy might reduce incidence of RP-ILD and improve survival in IIM-ILD patients. Anti-PM-Scl75 and anti-MDA5 antibodies could predict RP-ILD and survival respectively. In addition to the most frequent diarrhea, hepatic insufficiency was closely related to dosage reduction or therapy discontinuation.Trial registration:ISRCTN.com, ISRCTN 10507540. Retrospectively registered.

Cardiovascular safety of the tyrosine kinase inhibitor nintedanib

Real-world Experience of Nintedanib Therapy in Idiopathic-inflammatory-myopathy-related Interstitial Lung Disease: Efficacy and Tolerability

The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis

Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease

Metabolic Proﬁling of Tyrosine Kinase Inhibitor Nintedanib Using Metabolomics.

Safety of Nintedanib in Treatment of Idiopathic Pulmonary Fibrosis: A Meta-analysis

The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials

Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

Efficacy and Safety of Nintedanib in Patients with Non-Small Cell Lung Cancer, and Novel Insights in Radiation-Induced Lung Toxicity

Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy

Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

An updated safety review of the drug treatments for idiopathic pulmonary fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Anti-fibrotic Effects of Nintedanib in Lung Fibroblasts Derived from Patients with Idiopathic Pulmonary Fibrosis.

Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model